NDUFA9
ENSG00000139180
Target class
Enzyme
Chromosome
12
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFA9
- Gene name
- NADH:ubiquinone oxidoreductase subunit A9
- Gene symbol
- NDUFA9
- Previous gene symbols
- NDUFS2L
- Protein name
- NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial (Complex I-39kD) (CI-39kD) (NADH-ubiquinone oxidoreductase 39 kDa subunit)
- SDR22E1
- CI-39k
- COQ11
- Gene biotype
- Protein coding
- Gene family
- Short chain dehydrogenase/reductase superfamily|NADH:ubiquinone oxidoreductase supernumerary subunits|Flavoproteins
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 25.23
- Tissue specificity (Gini)
- 0.182
- Tissue specificity (tau)
- 0.526
- KEGG gene identifiers
- hsa:4704
- Protein interaction confidence
- 0.918301
- Protein interaction partners
- 113
- R-HSA-611105
- R-HSA-6799198
- End position
- 4694317
- Start position
- 4649095
- Chromosome
- 12
- Strand
- Forward
- Mitochondrion matrix .
- Mitochondria
- Nucleoplasm
Publication evidence
- PubMed 12611891
- Tissue specificity (tau)
- 0.526343
- Expression inequality (Gini)
- 0.182407
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 25.23
- Heart - Left Ventricle
- 24.57
- Muscle - Skeletal
- 24.51
- Brain - Cerebellar Hemisphere
- 21.68
- Brain - Cerebellum
- 17.49
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes25.23
- Heart - Left Ventricle24.57
- Muscle - Skeletal24.51
- Brain - Cerebellar Hemisphere21.68
- Brain - Cerebellum17.49
- Heart - Atrial Appendage17.11
- Colon - Transverse17.05
- Kidney - Medulla14.88
- Cells - Cultured fibroblasts14.71
- Small Intestine - Terminal Ileum14.39
- Brain - Frontal Cortex (BA9)13.91
- Colon - Sigmoid13.71
- Esophagus - Mucosa13.49
- Uterus13.34
- Esophagus - Muscularis13.31
- Adrenal Gland13.08
- Esophagus - Gastroesophageal Junction12.58
- Nerve - Tibial12.55
- Stomach12.54
- Bladder12.39
- Artery - Tibial12.27
- Cervix - Ectocervix12.22
- Fallopian Tube12.2
- Skin - Sun Exposed (Lower leg)12.19
- Thyroid12.17
And 29 more, listed on the interactive page.
Biological processes
- GO:0007623
- GO:0005634
- GO:0005739
- GO:0005743
- GO:0005759
- GO:0031966
- GO:0045271
- GO:0003954
- GO:0005515
- GO:0044877
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor